VERU News and Press, Veru Inc. From 02/19/26

MIAMI, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced that Mitchell Steiner, M.D., Chairman, President and Chief ...

2026-02-11 13:55:14 ET More on Veru Veru Inc. (VERU) Q1 2026 Earnings Call Transcript Veru Inc. (VERU) Q4 2025 Earnings Call Transcript Veru outlines 72-week Phase IIb PLATEAU study targeting obesity plateau population following FDA guidance Seeking Alpha...

2026-02-11 13:54:27 ET Veru Inc. (VERU) Q1 2026 Earnings Call February 11, 2026 8:00 AM EST Company Participants Samuel Fisch - Executive Director of Investor Relations & Corporate Communications Mitchell Steiner - Chairman, President & CEO Michele Greco - ...

2026-02-11 08:53:42 ET Image source: The Motley Fool. Wednesday, Feb. 11, 2026 at 8 a.m. ET Need a quote from a Motley Fool analyst? Email pr@fool.com Continue reading

2026-02-11 06:31:36 ET More on Veru Veru Inc. (VERU) Q4 2025 Earnings Call Transcript Veru outlines 72-week Phase IIb PLATEAU study targeting obesity plateau population following FDA guidance Seeking Alpha’s Quant Rating on Veru Historical earnings dat...

-- Phase 2b PLATEAU clinical trial evaluating enobosarm in combination with semaglutide in older patients with obesity on track to initiate this quarter— --Company to host conference call and webcast today at 8:00 a.m. ET-- MIAMI, FL, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (N...

Sun Life Financial Inc. (SLF) is expected to report $1.35 for Q4 2025 Copa Holdings S.A. Class A (CPA) is expected to report $4.4 for Q4 2025 Nabors Industries Ltd. (NBR) is expected to report $-2.93 for Q4 2025 Intercorp Financial Services Inc. (IFS) is expected to report $1.1 for Q4...

2026-02-10 09:58:04 ET More on Veru Veru Inc. (VERU) Q4 2025 Earnings Call Transcript Veru outlines 72-week Phase IIb PLATEAU study targeting obesity plateau population following FDA guidance Seeking Alpha’s Quant Rating on Veru Historical earnings dat...

MIAMI, FL, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced it will host a conference call and audio webcast on Wed...

2025-12-17 12:01:29 ET More on Veru Veru Inc. (VERU) Q4 2025 Earnings Call Transcript Veru announces pricing of $25 million public offering Veru announces proposed public offering Seeking Alpha’s Quant Rating on Veru Historical earnings data fo...